IHM
NGNE icon

Iguana Healthcare Management’s Neurogene NGNE Stock Holding History

Iguana Healthcare Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,250
Closed -$312K – 80
2015
Q4 		$312K Buy
+1,250
New +$329K 0.1% 63

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Iguana Healthcare Management's NGNE Position: Q1 2016 in Review

Iguana Healthcare Management sold out of Neurogene (NGNE) in Q1 2016, closing a stake of 1,250 shares — an estimated $312K sold.

Iguana Healthcare Management first reported a position in NGNE in Q4 2015 and held it in 1 quarter. The position peaked at $312K in Q4 2015. 35 funds tracked by Wall St. Rank hold NGNE as of Q1 2016.

  • Iguana Healthcare Management reported no remaining Neurogene position as of Q1 2016 after selling out during the quarter.
  • Iguana Healthcare Management sold 1,250 Neurogene shares in Q1 2016, an estimated $312K.
  • Iguana Healthcare Management first reported a position in Neurogene in Q4 2015 and held it in 1 quarter.
  • Iguana Healthcare Management's Neurogene position peaked at $312K in Q4 2015.
  • 35 funds tracked by Wall St. Rank held Neurogene as of Q1 2016.

Based on Iguana Healthcare Management's 13F filing for Q1 2016, filed 17 May 2016.